Nature Reviews Drug Discovery 16, 843–862 (2017)
In the version of this article that was originally published, there was an error in Figure 3 on page 847. In this figure, the structure attributed to the compound BMS-986165 is incorrect and the correct structure for this compound has not yet been disclosed. This error has now been corrected in the online version of the article, and the structure of SAR-20347 has been added instead. We apologize for any inconvenience that this error may have caused.
Additional information
The online version of the original article can be found at 10.1038/nrd.2017.201
Rights and permissions
About this article
Cite this article
Schwartz, D., Kanno, Y., Villarino, A. et al. Erratum: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 17, 78 (2018). https://doi.org/10.1038/nrd.2017.267
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd.2017.267
This article is cited by
-
Immunotherapy for ulcerative colitis: targeting innate and adaptive immune responses for better clinical outcomes
The Egyptian Journal of Internal Medicine (2025)
-
JAK inhibitors: a new choice for diabetes mellitus?
Diabetology & Metabolic Syndrome (2025)
-
Identification of novel covalent JAK3 inhibitors through consensus scoring virtual screening: integration of common feature pharmacophore and covalent docking
Molecular Diversity (2025)
-
Real‑world safety and efficacy of biological agents in inflammatory bowel disease: a one-year post-marketing pharmacovigilance observational study in the Calabria region
Pharmacological Reports (2025)
-
Atopic dermatitis: a comprehensive updated review of this intriguing disease with futuristic insights
Inflammopharmacology (2025)
